T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis

Journal of Neuroimmunology

Volumn 99, Issue 1, 1999, Pages 91-96

  Ristori, Giovanni ^a   Montesperelli, Chiara ^a   Gasperini, Claudio ^b   Battistini, Luca ^c   Borsellino, Giovanna ^c   Buttinelli, Carla ^a   Cannoni, Stefania ^a   Perna, Alessia ^a   Pozzilli, Carlo ^a   Salvetti, Marco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Interferon beta; Multiple sclerosis; Myelin basic protein; T lymphocytes

Indexed keywords

EPITOPE; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 4; MYELIN BASIC PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; DRUG EFFECT; EPITOPE MAPPING; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; AUTOIMMUNE DISEASES; BIOLOGICAL RESPONSE MODIFIERS; FEMALE; HUMANS; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-4; MALE; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032877123     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00107-1     Document Type: Article

References (34)

1. Amor S., Baker D., Layward L., McCormack K., van Noort J. Multiple sclerosis: a variation on a theme. Immunol. Today. 18:1997;368-371.
2. Brod S.A., Nelson L.D., Khan M., Wolinsky J.S. IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. Int. J. Neurosci. 90:1997;135-144.
3. Burns J., Bartgolpmew B., Lobo S. Isolation of myelin basic protein-specific T cells predominantly from the memory T cell compartment in multiple sclerosis. Ann. Neurol. 45:1999;33-39.
4. Confavreux C., Aimard G., Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 103:1980;281-300.
5. Dayal A.S., Jensen M.A., Lledo A., Arnason B.G.W. Interferon-gamma secreting cells in multiple sclerosis patients treated with interferon beta 1b. Neurology. 45:1995;2173-2177.
6. Eylar E.H., Kniskern P.J., Jackson J.J. Myelin basic proteins. Meth. Enzymol. 32B:1979;323-341.
7. Ferber I.A., Brocke S., Taylor-Edwards C.et al. Mice with a disrupted IFNγ gene are susceptible to the induction of experimental autoimmune encephalomyelitis. J. Immunol. 156:1996;5-7.
8. Frei K., Eugster H.P., Bopst M., Constantinescu C.S., Lavi E., Fontana A. Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185:1997;2177-2182.
9. Genain C.P., Lee-parrotz D., Nguyen M.H.et al. In healthy primates, circulating autoreactive T cells mediate autoimmune disease. J. Clin. Invest. 94(3):1994;1339-1345.
10. Goebels N., Schmidt H., Brunner C.H.et al. Long-term development of the human MBP specific T cell repertoire: epitope spreading versus clonal persistence. Neurology. 50:1998;A359.
11. Inaba K., Kitaura M., Kato T.et al. Contrasting effects of alpha/beta and gamma-interferons on expression of macrophage Ia antigens. J. Exp. Med. 163:1986;1030-1035.
12. Kurtzke J. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
13. LaFaille J.J., van de Keere F., Hsu A.L.et al. Myelin basic protein specific Th2 cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protecting them from the disease. J. Exp. Med. 186:1991;307-312.
14. Lehman P.V., Sercarz E.E., Forsthuber T., Dayan A.M., Gammon G. Determinant spreading and the dynamics of the autoimmunity T-cell repertoire. Immunol. Today. 14:1993;155-157.
15. Lublin F.D., Whitaker J.N., Eidelman B.H., Miller A.E., Arnason B.G.W., Burks J.S. Management of patients receiving interferon beta-1b for multiple sclerosis. Neurology. 46:1996;12-18.
16. McFarland H.F. Complexities in the treatment of autoimmune disease. Science. 274:1996;2037-2038.
17. Medaer R., Stinissen P., Truyen L., Raus J., Zhang J. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet. 346:1995;807-808.
18. Meinl E., Weber F., Drexler K., Morelle C.et al. Myelin basic protein-specific T lymphocyte response in multiple sclerosis. J. Clin. Invest. 92:1993;2633-2643.
19. Ota K., Matsui M., Milford E.L., Mackin G.A., Weiner H.L., Hafler D.A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 346:1990;183-187.
20. Pette M., Fujita K., Kitzke B.et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology. 40:1990;1770-1776.
21. Pette M., Pette D.F., Muraro P.A., Farnon E., Martin R., McFarland H.F. Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology. 49:1997;385-392.
22. Poser C.M., Paty D.W., Scheinberg L.et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
23. Ristori G., Buttinelli C., Pozzilli C., Fieschi C., Salvetti M. Microbe exposure, innate immunity and autoimmunity. Immunol. Today. 20:1999;54.
24. Rudick R.A., Cohen J.A., Weinston-Guttman B.W., Kinkel R.P., Sanshoff M. Management of multiple sclerosis. New Engl. J. Med. 337:1997;1604-1611.
25. Rudick R.A., Ransohoff R.M., Lee J.C., Peppler R.et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 50:1998;1294-1300.
26. Salvetti M., Ristori G., D'Amato M.et al. Predominant and stable responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis. Eur. J. Immunol. 23:1993;1232-1239.
27. Tuohy V.K., Yu M., Weinstock-Guttman B., Kinkel R.P. Diversity and plasticity of self recognition during the development of multiple sclerosis. J. Clin. Invest. 99:1997;1682-1690.
28. Tuohy V.K., Yu M., Yin L., Kawcrzac J.A., Kinkel R.P. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 189:1999;1033-1042.
29. Uccelli A., Giunti D., Salvetti M.et al. A restricted T cell response to myelin basic protein is stable in multiple sclerosis patients. Clin. Exp. Immunol. 111:1998;186-192.
30. Valli A., Sette A., Kappos L.et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J. Clin. Invest. 91:1993;616-628.
31. Weber F., Janovskaja J., Polak T., Poase S., Rieckmann P. Effect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1b. Neurology. 52(5):1999;1069-1071.
32. Willemborg D.O., Fordhan S., Bernard C.C.A., Cowden W.B., Ramshaw I.A. IFNγ plays a critical down-regulation role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157:1996;3223-3227.
33. Wucherpfennig K.W., Zhang J., Witek C.et al. Clonal expansion and persistence of human T cell specific for an immunodominant myelin basic protein peptide. J. Immunol. 152:1994;5581-5592.
34. Zhang J., Markovic S., Lacet B.et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with miultiple sclerosis. J. Exp. Med. 179:1994;973-984.